
Opinion|Videos|March 25, 2024
Widening the Therapeutic Window in The Management of Parkinson’s Disease
Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.
Advertisement
Episodes in this series
Timecodes:
1:20 Long-term challenges
2:58 Fluctuations in benefits
6:35 Therapeutic window
11:40 Amantadine ER for PD
14:33 Dyskinesia and treatment
18:18 Amantadine patients
23:14 Amantadine formulations
27:59 Early treatment & future
Advertisement
Related to this article

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.

Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
2
Remibrutinib Phase 3 Results in RMS, Blood Pressure Variability Findings, and Updated Stroke Rehabilitation Guidelines
3
How MS Understanding Has Evolved: Activity, Impact, and Progression
4
Episode 178: Evolving Approaches to Epilepsy Clinical Trial Design
5



